CA2997103C - Anticorps anti-survivine pour le traitement du cancer - Google Patents

Anticorps anti-survivine pour le traitement du cancer

Info

Publication number
CA2997103C
CA2997103C CA2997103A CA2997103A CA2997103C CA 2997103 C CA2997103 C CA 2997103C CA 2997103 A CA2997103 A CA 2997103A CA 2997103 A CA2997103 A CA 2997103A CA 2997103 C CA2997103 C CA 2997103C
Authority
CA
Canada
Prior art keywords
seq
antibody
sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2997103A
Other languages
English (en)
Other versions
CA2997103A1 (fr
Inventor
Robert A. Fenstermaker
Michael J. Ciesielski
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Priority claimed from PCT/US2016/050391 external-priority patent/WO2017041092A2/fr
Publication of CA2997103A1 publication Critical patent/CA2997103A1/fr
Application granted granted Critical
Publication of CA2997103C publication Critical patent/CA2997103C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des anticorps spécifiques de la survivine, des acides nucléiques codant pour les anticorps et des procédés de traitement de tumeurs comprenant des cellules exprimant la survivine par administration de ces anticorps. Les compositions d'anticorps se sont révélées être efficaces dans l'inhibition de la croissance de tumeurs.
CA2997103A 2015-09-04 2016-09-06 Anticorps anti-survivine pour le traitement du cancer Active CA2997103C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
US62/214,242 2015-09-04
PCT/US2016/050391 WO2017041092A2 (fr) 2015-09-04 2016-09-06 Anticorps anti-survivine pour le traitement du cancer

Publications (2)

Publication Number Publication Date
CA2997103A1 CA2997103A1 (fr) 2017-03-09
CA2997103C true CA2997103C (fr) 2026-02-24

Family

ID=

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
US11773181B2 (en) Anti-survivin antibodies for cancer therapy
JP7604379B2 (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
WO2017215585A1 (fr) Anticorps monoclonal anti-cd47 et application correspondante
US10662250B2 (en) Humanized monoclonal antibody specific to syndecan-1
TW201329103A (zh) 抗－ＥｒｂＢ３抗體及其用途
KR20240099351A (ko) Gprc5d에 결합하는 항체 및 그 용도
CN118240082A (zh) Pd-1结合分子及其应用
CN117280034A (zh) 间皮素结合分子及其应用
CN114685667B (zh) 间皮素结合分子及其应用
US12516123B2 (en) Anti-PD-L1 antibody and pharmaceutical use thereof
CA2997103C (fr) Anticorps anti-survivine pour le traitement du cancer
WO2022023292A9 (fr) Anticorps ciblant la protéine de spicule de coronavirus et leur utilisation
WO2021043810A1 (fr) Anticorps anti-fucosyl-gm1
KR102942600B1 (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
US12331133B2 (en) Therapeutic antibodies for treating lung cancer
US20240317844A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases